Medtronic plc (NYSE: MDT) approved a cash dividend of $0.72 per ordinary share for the second quarter of fiscal year 2027. The board authorized the payout on August 20, 2026, maintaining the trajectory set by its June 2026 announcement of an annual dividend increase.

The declaration reinforces Medtronic’s status as a constituent of the S&P 500 Dividend Aristocrats index. The company has raised its annual dividend payment for 49 consecutive years, signaling consistent capital return discipline to shareholders.

Dividend Schedule

The dividend is payable on October 16, 2026. Shareholders must be on record at the close of business on September 25, 2026, to receive the distribution.

Corporate Context

Headquartered in Galway, Ireland, Medtronic operates as a global healthcare technology company. Its portfolio addresses 70 health conditions through cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems. The company employs more than 95,000 people across 150 countries.

A federal jury has ordered Medtronic to pay $88 million to Larry Patterson and his wife, Tammy, after finding that hernia mesh manufactured by its Covidien unit caused Larry serious injuries and that his physicians were never adequately warned of the risks. The verdict was delivered on August 4, 2026, before U.S. District Judge Patti B. Saris in Boston, and represents the highest compensatory damages award in the 15-year history of mesh products litigation in the United States—surpassing all prior hernia mesh and transvaginal mesh trial outcomes.

Case Background and Injuries

Larry Patterson, 61, was implanted with a Symbotex hernia mesh during a hernia repair procedure in 2017. According to trial evidence, the mesh's protective collagen coating dissolved in approximately seven days—far sooner than the 30 days physicians were told to expect—causing the mesh to adhere to his bowel. Patterson subsequently underwent a second surgery to remove the mesh, along with several inches of his intestine. Both Larry and Tammy Patterson testified about the impact the past six years have had on their lives.

The jury found that Covidien failed to warn physicians about the risks associated with the mesh. The verdict breakdown is outlined below:

Covidien denied the allegations throughout the trial, arguing that Larry Patterson's medical history and other risk factors were responsible for his injuries.

Timeline of the Litigation

Patterson's case was the first of more than 2,400 lawsuits against Covidien to reach a jury, arising from federal multidistrict litigation MDL No. 3029, which coordinates claims that Covidien's hernia mesh products—including Parietex, ProGrip, and Symbotex—were defectively designed and inadequately labeled. The key milestones in the litigation are summarized below:

The case is formally identified as Patterson v. Covidien Inc., No. 1:22-cv-10153, a member case in MDL 3029, pending in the U.S. District Court for the District of Massachusetts. This verdict resolves only the Pattersons' individual claims.

Legal Representation

Timothy M. O'Brien, shareholder at Levin, Papantonio, Proctor, Buchanan, O'Brien, Barr & Mougey, P.A., led the trial team. Kelsey Stokes of Stokes & Hobbs handled key witnesses and tried the case alongside O'Brien. Levin Papantonio attorneys Alex Taylor and Caleb Cunningham contributed to developing important trial testimony, including that of Patterson's implanting surgeon, whose testimony as a neutral witness supported the failure-to-warn claims.

O'Brien serves on the Plaintiffs' Executive Committee within the Covidien Hernia Mesh MDL. Commenting on the outcome, O'Brien stated: "This is a substantial verdict for the substantial damage caused to this wonderful man and his wife. The jury found this company concealed the truth about Symbotex, and hit them with the consequences."

About Levin Papantonio

Founded in 1955, Levin Papantonio has represented individuals and families harmed by dangerous products and corporate misconduct, helping to secure over $85 billion in verdicts and settlements for clients across the country. The firm has served in leadership roles in many of the nation's largest mass tort cases and continues to advocate for clients in complex pharmaceutical, medical device, environmental, and products liability litigation.